Biotech Values

[genisi]

No. I think an approvable letter is more likely. I don't think the FDA will be comfortable with laropiprant safety yet (there are no long-term usage data for it).

BTW, after looking here the data we're discussing were pulled from these 4 trials started on Jun. 2007:

http://clinicaltrials.gov/ct2/show/NCT00479882?term=Cordaptive+MK-0524B&rank=1

I think that the Niaspan used in the trial was not the more recently introduced version (lower flushing incidence) so another point that can narrow the difference.